sumatriptan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
serotonin (5-HT1) receptor agonists, sumatriptan derivatives 2543 103628-46-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • GR43175
  • GR 43175
  • sumatriptan
  • sumatriptan succinate
A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
  • Molecular weight: 295.40
  • Formula: C14H21N3O2S
  • CLOGP: 0.74
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 65.20
  • ALOGS: -3.37
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg N
50 mg O
6 mg P
25 mg R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 21.40 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 22 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.68 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 14 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 19 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.83 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK,TGFBR1 18
kinase-selectivity-class AAK1,AXL,FLT3,LRRK2,PDK1,TEK 6
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 2.075 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1
rat-kpuu-brain Rat brain Kpuu 0.017 % High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 28, 1992 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product physical issue 4111.25 11.53 911 58632 4749 90564155
Product dose omission issue 1122.79 11.53 1157 58386 290530 90278374
Application site erythema 584.98 11.53 192 59351 5016 90563888
Migraine 474.06 11.53 604 58939 189788 90379116
Application site burn 380.74 11.53 95 59448 879 90568025
Device malfunction 343.72 11.53 198 59345 20779 90548125
Product quality issue 337.38 11.53 333 59210 78992 90489912
Application site pain 332.92 11.53 123 59420 4597 90564307
Device deployment issue 328.21 11.53 123 59420 4786 90564118
Medication overuse headache 272.72 11.53 80 59463 1421 90567483
Swollen tongue 269.57 11.53 231 59312 45725 90523179
Application site discolouration 266.68 11.53 71 59472 867 90568037
Device issue 256.30 11.53 187 59356 29350 90539554
Headache 248.56 11.53 1171 58372 861575 89707329
Reversible cerebral vasoconstriction syndrome 245.57 11.53 95 59448 4035 90564869
Application site paraesthesia 199.57 11.53 36 59507 43 90568861
Colitis ischaemic 195.50 11.53 114 59429 12232 90556672
Drug ineffective for unapproved indication 184.07 11.53 223 59320 66421 90502483
Swelling face 181.78 11.53 245 59298 81107 90487797
Serotonin syndrome 168.36 11.53 163 59380 37724 90531180
Glossodynia 165.32 11.53 12 59531 321767 90247137
Angioedema 156.68 11.53 203 59340 64673 90504231
Dysphonia 154.87 11.53 199 59344 62885 90506019
Systemic lupus erythematosus 152.40 11.53 27 59516 361869 90207035
Pericarditis 151.41 11.53 6 59537 270145 90298759
Accidental exposure to product 151.32 11.53 162 59381 42204 90526700
Drug ineffective 148.96 11.53 1472 58071 1382826 89186078
Wound 148.18 11.53 14 59529 302966 90265938
Infusion related reaction 146.21 11.53 46 59497 416734 90152170
Application site urticaria 146.16 11.53 34 59509 226 90568678
Application site rash 139.75 11.53 56 59487 2613 90566291
Arthropathy 134.70 11.53 37 59506 366205 90202699
Product complaint 129.80 11.53 91 59452 13409 90555495
Application site irritation 126.96 11.53 48 59495 1913 90566991
Arteriospasm coronary 125.81 11.53 63 59480 4987 90563917
Throat tightness 121.97 11.53 122 59421 29362 90539542
Application site pruritus 117.78 11.53 57 59486 4190 90564714
Folliculitis 116.35 11.53 4 59539 204349 90364555
Lower respiratory tract infection 109.26 11.53 17 59526 250642 90318262
Application site warmth 108.57 11.53 27 59516 246 90568658
Coronary artery dissection 106.43 11.53 35 59508 919 90567985
Contraindicated product administered 102.53 11.53 41 59502 320098 90248806
Hepatic enzyme increased 101.94 11.53 55 59488 360681 90208223
Injection site pain 99.56 11.53 295 59248 173404 90395500
Anxiety 99.39 11.53 435 59108 309337 90259567
Impaired healing 95.28 11.53 19 59524 234180 90334724
Synovitis 95.05 11.53 49 59494 329703 90239201
Chest discomfort 92.01 11.53 248 59295 138117 90430787
Joint swelling 91.46 11.53 118 59425 503182 90065722
Emotional distress 88.93 11.53 115 59428 36547 90532357
Injection site haemorrhage 88.52 11.53 101 59442 28217 90540687
General physical health deterioration 88.07 11.53 63 59480 355052 90213852
Application site scar 87.54 11.53 22 59521 210 90568694
Wrong technique in product usage process 84.29 11.53 161 59382 71410 90497494
Muscle twitching 83.70 11.53 91 59452 24111 90544793
Application site vesicles 83.50 11.53 33 59510 1484 90567420
Concussion 82.37 11.53 64 59479 11027 90557877
Post-traumatic neck syndrome 79.70 11.53 37 59506 2477 90566427
Swelling 79.51 11.53 95 59448 418963 90149941
Endometriosis 79.11 11.53 50 59493 6198 90562706
Product substitution issue 77.23 11.53 76 59467 17932 90550972
Hostility 76.90 11.53 35 59508 2238 90566666
Suicidal ideation 75.97 11.53 157 59386 73698 90495206
Libido increased 75.70 11.53 32 59511 1712 90567192
Needle issue 75.54 11.53 67 59476 13867 90555037
Abdominal discomfort 74.85 11.53 124 59419 477204 90091700
Dizziness 74.01 11.53 649 58894 588635 89980269
Soft tissue injury 73.27 11.53 33 59510 2059 90566845
Application site swelling 73.24 11.53 24 59519 623 90568281
Treatment failure 72.66 11.53 56 59487 303872 90265032
Type 2 diabetes mellitus 71.96 11.53 22 59521 203222 90365682
Tremor 71.14 11.53 242 59301 152931 90415973
IIIrd nerve paresis 70.77 11.53 17 59526 132 90568772
Clonus 70.28 11.53 45 59498 5705 90563199
Migraine without aura 69.60 11.53 24 59519 731 90568173
Stomatitis 69.05 11.53 48 59495 274650 90294254
Liver injury 69.02 11.53 14 59529 170553 90398351
Cerebral vasoconstriction 68.47 11.53 27 59516 1207 90567697
Death 68.47 11.53 122 59421 456429 90112475
Somnolence 68.05 11.53 295 59248 208789 90360115
Sternal fracture 66.04 11.53 34 59509 2853 90566051
Alopecia 65.86 11.53 142 59401 494929 90073975
Rheumatoid arthritis 63.79 11.53 87 59456 362527 90206377
Nightmare 63.74 11.53 75 59468 21650 90547254
Injection site bruising 63.23 11.53 119 59424 52188 90516716
Cholecystitis chronic 62.96 11.53 52 59491 9774 90559130
Blister 62.20 11.53 46 59497 254952 90313952
Feeling abnormal 59.90 11.53 243 59300 166992 90401912
Joint range of motion decreased 59.54 11.53 9 59534 135634 90433270
C-reactive protein abnormal 59.40 11.53 7 59536 127422 90441482
Device power source issue 59.03 11.53 22 59521 842 90568062
Nausea 58.06 11.53 1037 58506 1109279 89459625
Application site dryness 58.01 11.53 15 59528 162 90568742
Somnambulism 57.59 11.53 41 59502 6187 90562717
Application site exfoliation 56.78 11.53 18 59525 419 90568485
Ill-defined disorder 55.47 11.53 26 59517 184865 90384039
Pituitary tumour benign 54.30 11.53 27 59516 2105 90566799
Product administration interrupted 54.08 11.53 53 59490 12439 90556465
Incorrect dose administered by device 53.59 11.53 38 59505 5699 90563205
Depression 53.26 11.53 359 59184 300242 90268662
Vasospasm 52.64 11.53 21 59522 968 90567936
Application site reaction 52.59 11.53 20 59523 810 90568094
Irritable bowel syndrome 52.45 11.53 36 59507 207412 90361492
Pulmonary fibrosis 52.43 11.53 5 59538 107498 90461406
Infection 52.26 11.53 99 59444 361995 90206909
Application site scab 52.20 11.53 14 59529 176 90568728
Peripheral swelling 52.05 11.53 122 59421 412984 90155920
Wound infection 51.75 11.53 5 59538 106397 90462507
Paraesthesia 51.15 11.53 310 59233 250016 90318888
Dysgeusia 50.87 11.53 109 59434 52451 90516453
Mobility decreased 50.61 11.53 54 59489 250680 90318224
Pharyngeal swelling 50.33 11.53 46 59497 9898 90559006
Gastrointestinal disorder 49.92 11.53 57 59486 256630 90312274
Facet joint syndrome 49.54 11.53 4 59539 98385 90470519
Acute kidney injury 49.46 11.53 84 59459 320303 90248601
Renal infarct 48.82 11.53 23 59520 1592 90567312
Product leakage 48.65 11.53 22 59521 1386 90567518
Cluster headache 48.42 11.53 19 59524 838 90568066
Vision blurred 48.36 11.53 171 59372 110122 90458782
Helicobacter infection 47.89 11.53 47 59496 226803 90342101
Blood cholesterol increased 47.60 11.53 40 59503 207972 90360932
Pre-existing condition improved 47.55 11.53 43 59500 9126 90559778
Tension headache 46.58 11.53 39 59504 7470 90561434
Device leakage 46.29 11.53 44 59499 9947 90558957
Pineal gland cyst 46.23 11.53 13 59530 197 90568707
Cervicogenic headache 46.11 11.53 13 59530 199 90568705
Stress cardiomyopathy 45.80 11.53 50 59493 13305 90555599
Disease progression 45.49 11.53 23 59520 156592 90412312
Product use issue 45.19 11.53 93 59450 329826 90239078
Inflammation 45.14 11.53 31 59512 178561 90390343
Cardiac failure 44.27 11.53 9 59534 109487 90459417
Hyperhidrosis 44.07 11.53 192 59351 136113 90432791
Peripheral venous disease 43.43 11.53 3 59540 83918 90484986
Expired product administered 43.04 11.53 36 59507 6886 90562018
Application site inflammation 42.48 11.53 14 59529 370 90568534
Therapeutic response unexpected 41.56 11.53 61 59482 21819 90547085
Poor quality sleep 41.46 11.53 65 59478 24628 90544276
Hypercholesterolaemia 41.40 11.53 8 59535 100884 90468020
Grip strength decreased 40.95 11.53 6 59537 92570 90476334
Hot flush 40.90 11.53 108 59435 59380 90509524
Cerebral venous thrombosis 40.88 11.53 23 59520 2305 90566599
Osteoarthritis 40.79 11.53 41 59502 195689 90373215
Anaemia 40.68 11.53 109 59434 352693 90216211
Lung disorder 40.64 11.53 24 59519 149859 90419045
Bursitis 40.28 11.53 18 59525 131636 90437268
Hyperreflexia 40.11 11.53 34 59509 6623 90562281
Red blood cell sedimentation rate increased 39.86 11.53 4 59539 82591 90486313
Pneumonia 39.71 11.53 251 59292 637808 89931096
Febrile neutropenia 39.33 11.53 28 59515 158321 90410583
Drug specific antibody 39.25 11.53 23 59520 2489 90566415
Application site bruise 39.04 11.53 13 59530 355 90568549
Neutropenia 38.48 11.53 55 59488 224849 90344055
Middle insomnia 38.22 11.53 51 59492 16700 90552204
Abortion spontaneous 38.04 11.53 99 59444 53957 90514947
Oedema 37.31 11.53 46 59497 200249 90368655
Meningoradiculitis 37.20 11.53 10 59533 127 90568777
Angle closure glaucoma 37.13 11.53 23 59520 2752 90566152
Muscle tightness 37.13 11.53 45 59498 13394 90555510
Wheezing 37.12 11.53 62 59481 238018 90330886
Incorrect route of product administration 36.95 11.53 94 59449 50532 90518372
Irritability 36.88 11.53 76 59467 35586 90533318
Pyrexia 36.54 11.53 269 59274 660216 89908688
Migraine with aura 36.30 11.53 24 59519 3212 90565692
Multiple sclerosis 34.47 11.53 64 59479 27776 90541128
Vertigo 33.89 11.53 112 59431 69699 90499205
Hip arthroplasty 33.57 11.53 5 59538 76203 90492701
Psoriatic arthropathy 33.30 11.53 62 59481 228273 90340631
Rash 33.10 11.53 349 59194 795751 89773153
Palpitations 32.94 11.53 177 59366 136551 90432353
Seizure 32.41 11.53 191 59352 152438 90416466
Sciatica 32.39 11.53 13 59530 101369 90467535
Photophobia 31.64 11.53 53 59490 21216 90547688
Discomfort 31.43 11.53 85 59458 274250 90294654
Atrial fibrillation 31.42 11.53 25 59518 133586 90435318
Decreased appetite 30.73 11.53 135 59408 376405 90192499
Extensor plantar response 30.33 11.53 16 59527 1411 90567493
Foetal heart rate abnormal 30.00 11.53 14 59529 948 90567956
Knee arthroplasty 29.44 11.53 9 59534 83173 90485731
Application site discomfort 29.37 11.53 11 59532 427 90568477
Hyponatraemia 28.95 11.53 27 59516 133511 90435393
Application site erosion 28.78 11.53 9 59534 200 90568704
Impaired quality of life 28.40 11.53 53 59490 23091 90545813
Nasopharyngitis 28.01 11.53 155 59388 406949 90161955
Secondary adrenocortical insufficiency 27.98 11.53 18 59525 2300 90566604
Blood pressure systolic increased 27.70 11.53 3 59540 58342 90510562
Pancytopenia 27.66 11.53 23 59520 120240 90448664
Nipple pain 27.47 11.53 10 59533 358 90568546
Flushing 27.34 11.53 123 59420 88368 90480536
Transient global amnesia 27.10 11.53 12 59531 719 90568185
Liver function test increased 26.91 11.53 11 59532 84844 90484060
Tinnitus 26.39 11.53 75 59468 43027 90525877
Interstitial lung disease 25.74 11.53 9 59534 76396 90492508
Renal tubular acidosis 25.56 11.53 17 59526 2298 90566606
Hyperprolactinaemia 25.31 11.53 24 59519 5409 90563495
Device difficult to use 25.18 11.53 43 59500 17482 90551422
Small for dates baby 25.02 11.53 23 59520 4984 90563920
Gait inability 24.86 11.53 36 59507 146420 90422484
Body temperature increased 24.69 11.53 75 59468 44635 90524269
Rib fracture 24.64 11.53 54 59489 26381 90542523
Dependence 24.63 11.53 16 59527 2079 90566825
Eyelid ptosis 24.62 11.53 30 59513 8976 90559928
Injection site laceration 24.60 11.53 7 59536 111 90568793
Prescribed overdose 24.59 11.53 17 59526 97608 90471296
Neonatal respiratory distress 24.55 11.53 11 59532 678 90568226
Withdrawal syndrome 24.48 11.53 49 59494 22475 90546429
Renal impairment 24.44 11.53 20 59523 105401 90463503
Muscle contractions involuntary 24.18 11.53 18 59525 2910 90565994
Drug-disease interaction 24.10 11.53 12 59531 938 90567966
Starvation ketoacidosis 24.08 11.53 8 59535 217 90568687
Lower limb fracture 23.92 11.53 13 59530 85000 90483904
Platelet count decreased 23.91 11.53 33 59510 136936 90431968
Loss of consciousness 23.91 11.53 166 59377 140072 90428832
Narcolepsy 23.86 11.53 14 59529 1518 90567386
Drug-induced liver injury 23.73 11.53 15 59528 90303 90478601
Diarrhoea 23.66 11.53 455 59088 938735 89630169
Foetal exposure during pregnancy 23.65 11.53 72 59471 42903 90526001
Haemoglobin decreased 23.58 11.53 44 59499 161912 90406992
Device defective 23.49 11.53 19 59524 3467 90565437
Infection reactivation 23.26 11.53 15 59528 1925 90566979
Hyperkalaemia 23.04 11.53 7 59536 64957 90503947
Blood testosterone increased 23.04 11.53 8 59535 249 90568655
Musculoskeletal pain 22.82 11.53 49 59494 171202 90397702
Pharyngeal oedema 22.77 11.53 36 59507 13735 90555169
Personality disorder 22.64 11.53 34 59509 12410 90556494
Gallbladder disorder 22.63 11.53 44 59499 19759 90549145
Musculoskeletal stiffness 22.58 11.53 109 59434 296423 90272481
Application site papules 22.55 11.53 6 59537 73 90568831
Myelosuppression 22.52 11.53 4 59539 53587 90515317
Night sweats 22.50 11.53 31 59512 128735 90440169
Illness 22.44 11.53 110 59433 81859 90487045
Post-traumatic stress disorder 22.44 11.53 25 59518 6803 90562101
Sunburn 22.43 11.53 18 59525 3249 90565655
Liver disorder 22.42 11.53 28 59515 121241 90447663
Therapeutic product effect decreased 22.34 11.53 100 59443 277471 90291433
Congenital hypoplasia of depressor angularis oris muscle 22.33 11.53 6 59537 76 90568828
Phonophobia 22.12 11.53 9 59534 437 90568467
Sleep talking 22.11 11.53 12 59531 1121 90567783
Injection site erythema 22.04 11.53 125 59418 98377 90470527
Foot deformity 21.94 11.53 6 59537 59645 90509259
Vasoconstriction 21.92 11.53 11 59532 874 90568030
Pulmonary artery stenosis congenital 21.75 11.53 9 59534 456 90568448
Thrombocytopenia 21.48 11.53 68 59475 208657 90360247
Intentional product use issue 21.39 11.53 72 59471 216820 90352084
Blood alkaline phosphatase 21.39 11.53 7 59536 181 90568723
Fibromyalgia 21.36 11.53 67 59476 206202 90362702
Meconium in amniotic fluid 21.23 11.53 8 59535 316 90568588
Autoimmune disorder 21.21 11.53 12 59531 76732 90492172
Multiple sclerosis relapse 21.14 11.53 79 59464 52226 90516678
Drug dependence 20.93 11.53 54 59489 29273 90539631
Surgery 20.89 11.53 71 59472 44816 90524088
Product adhesion issue 20.75 11.53 21 59522 5121 90563783
Hypertonia 20.71 11.53 21 59522 5134 90563770
Injection site injury 20.67 11.53 11 59532 988 90567916
Spleen congestion 20.59 11.53 6 59537 104 90568800
Pleural effusion 20.55 11.53 26 59517 111965 90456939
Malignant neoplasm progression 20.47 11.53 24 59519 106846 90462058
Delirium 20.46 11.53 23 59520 104336 90464568
Hyperacusis 20.39 11.53 16 59527 2795 90566109
Gamma-glutamyltransferase abnormal 20.35 11.53 9 59534 538 90568366
Adjustment disorder with depressed mood 20.33 11.53 6 59537 56747 90512157
Blood creatinine increased 20.26 11.53 22 59521 101364 90467540
Large intestinal ulcer haemorrhage 20.07 11.53 6 59537 114 90568790
Optic ischaemic neuropathy 19.67 11.53 13 59530 1739 90567165
Blepharospasm 19.61 11.53 6 59537 55439 90513465
Basilar migraine 19.60 11.53 5 59538 51 90568853
Biliary dyskinesia 19.30 11.53 15 59528 2584 90566320
Major depression 19.09 11.53 28 59515 10007 90558897
Foreign body in reproductive tract 18.98 11.53 11 59532 1166 90567738
Disturbance in attention 18.91 11.53 71 59472 47038 90521866
Depressive symptom 18.49 11.53 20 59523 5265 90563639
Injection site swelling 18.35 11.53 83 59460 59756 90509148
Application site dermatitis 18.26 11.53 6 59537 157 90568747
Septic shock 18.26 11.53 17 59526 84143 90484761
Nail disorder 18.18 11.53 8 59535 59059 90509845
Complement factor C4 decreased 18.12 11.53 7 59536 296 90568608
Device use error 18.05 11.53 23 59520 7198 90561706
Burns third degree 17.83 11.53 7 59536 309 90568595
Complement factor C3 decreased 17.83 11.53 7 59536 309 90568595
Drug specific antibody present 17.80 11.53 20 59523 5494 90563410
Oxygen saturation decreased 17.67 11.53 27 59516 107456 90461448
Gastrointestinal haemorrhage 17.57 11.53 20 59523 90228 90478676
Acute coronary syndrome 17.51 11.53 28 59515 10785 90558119
C-reactive protein increased 17.35 11.53 61 59482 181328 90387576
Subclavian artery thrombosis 17.30 11.53 6 59537 186 90568718
Burning sensation 17.26 11.53 85 59458 63367 90505537
Chest pain 17.07 11.53 300 59243 319345 90249559
Laryngitis 17.06 11.53 6 59537 50747 90518157
Superior sagittal sinus thrombosis 17.03 11.53 9 59534 797 90568107
Bipolar disorder 16.99 11.53 25 59518 8960 90559944
Anaphylactic reaction 16.97 11.53 107 59436 87417 90481487
Acute myocardial infarction 16.95 11.53 56 59487 34834 90534070
Sleep disorder 16.75 11.53 70 59473 197960 90370944
Respiratory disorder 16.70 11.53 11 59532 64805 90504099
Drug withdrawal syndrome 16.63 11.53 49 59494 28674 90540230
Myalgia 16.56 11.53 182 59361 174943 90393961
Deep vein thrombosis 16.53 11.53 110 59433 91510 90477394
Dermatitis atopic 16.52 11.53 43 59500 23429 90545475
Ischaemic cerebral infarction 16.48 11.53 11 59532 1495 90567409
Human chorionic gonadotropin decreased 16.30 11.53 5 59538 104 90568800
Transverse sinus thrombosis 16.27 11.53 8 59535 609 90568295
Lip swelling 16.18 11.53 59 59484 38551 90530353
Cognitive disorder 16.13 11.53 89 59454 69318 90499586
Abortion missed 15.95 11.53 12 59531 1970 90566934
Injury associated with device 15.81 11.53 17 59526 4447 90564457
Frequent bowel movements 15.59 11.53 9 59534 56926 90511978
Acute oesophageal mucosal lesion 15.59 11.53 5 59538 121 90568783
Post viral fatigue syndrome 15.46 11.53 6 59537 257 90568647
Hypotension 15.43 11.53 138 59405 325259 90243645
Gallbladder injury 15.42 11.53 10 59533 1296 90567608
Panic attack 15.29 11.53 45 59498 26320 90542584
Wrong technique in device usage process 15.25 11.53 19 59524 5816 90563088
Exostosis 15.13 11.53 8 59535 53126 90515778
Sepsis 14.93 11.53 64 59479 179750 90389154
Sedation 14.91 11.53 67 59476 48104 90520800
Live birth 14.90 11.53 18 59525 79089 90489815
Teratogenicity 14.87 11.53 6 59537 285 90568619
Asthenia 14.83 11.53 254 59289 533497 90035407
Injection site urticaria 14.79 11.53 35 59508 17976 90550928
Trismus 14.73 11.53 17 59526 4804 90564100
Hepatic function abnormal 14.68 11.53 6 59537 46282 90522622
Influenza like illness 14.68 11.53 97 59446 80514 90488390
Vomiting projectile 14.67 11.53 11 59532 1798 90567106
Paraesthesia oral 14.66 11.53 50 59493 31609 90537295
Cholestasis 14.63 11.53 3 59540 36296 90532608
Hypotonia neonatal 14.59 11.53 10 59533 1420 90567484
Sleep apnoea syndrome 14.58 11.53 50 59493 31697 90537207
Drug dose omission by device 14.56 11.53 25 59518 10206 90558698
Chemical burn 14.55 11.53 7 59536 508 90568396
Cholecystectomy 14.52 11.53 27 59516 11728 90557176
Hepatotoxicity 14.44 11.53 6 59537 45836 90523068
Immunisation reaction 14.31 11.53 8 59535 792 90568112
Lichen planus 14.30 11.53 13 59530 2778 90566126
Osteoporosis 14.25 11.53 26 59517 96505 90472399
Blood HIV RNA increased 14.09 11.53 8 59535 816 90568088
Left atrial volume increased 14.08 11.53 4 59539 63 90568841
Intervertebral disc injury 14.06 11.53 5 59538 167 90568737
Cerebral venous sinus thrombosis 14.04 11.53 12 59531 2364 90566540
Application site laceration 13.97 11.53 3 59540 13 90568891
Coeliac disease 13.80 11.53 6 59537 44604 90524300
Joint dislocation 13.78 11.53 6 59537 44576 90524328
Confusional state 13.78 11.53 175 59368 386030 90182874
Mood altered 13.74 11.53 33 59510 17111 90551793
Neoplasm progression 13.73 11.53 6 59537 44480 90524424
Pneumonia aspiration 13.49 11.53 5 59538 40935 90527969
Dysmenorrhoea 13.49 11.53 16 59527 4656 90564248
Rash maculo-papular 13.49 11.53 5 59538 40928 90527976
Potassium wasting nephropathy 13.43 11.53 4 59539 75 90568829
Periodic limb movement disorder 13.42 11.53 7 59536 603 90568301
Onychomycosis 13.30 11.53 4 59539 37372 90531532
Ovarian neoplasm 13.23 11.53 8 59535 917 90567987
Incorrect dose administered 13.19 11.53 93 59450 78837 90490067
Amyloidoma 13.16 11.53 3 59540 18 90568886
Product storage error 13.15 11.53 36 59507 20205 90548699
Dyskinesia 12.99 11.53 53 59490 36481 90532423
Intentional dose omission 12.95 11.53 33 59510 17750 90551154
Temperature intolerance 12.87 11.53 26 59517 12004 90556900
Nasal discomfort 12.82 11.53 17 59526 5531 90563373
Depressed mood 12.76 11.53 66 59477 50156 90518748
Sensory disturbance 12.71 11.53 30 59513 15383 90553521
Head discomfort 12.62 11.53 31 59512 16302 90552602
Obesity 12.60 11.53 32 59511 105475 90463429
Anhedonia 12.58 11.53 25 59518 11406 90557498
Mouth swelling 12.55 11.53 17 59526 5645 90563259
Osteonecrosis of jaw 12.51 11.53 5 59538 39098 90529806
Toxic epidermal necrolysis 12.48 11.53 3 59540 32525 90536379
Varicella zoster virus infection 12.41 11.53 14 59529 3863 90565041
Premature delivery 12.33 11.53 5 59538 38757 90530147
Hepatic cirrhosis 12.33 11.53 14 59529 63239 90505665
Bone marrow failure 12.31 11.53 3 59540 32218 90536686
Sinus tachycardia 12.31 11.53 44 59499 28469 90540435
Neuralgia 12.25 11.53 47 59496 31453 90537451
Suicidal behaviour 12.19 11.53 12 59531 2832 90566072
Cerebral mass effect 12.19 11.53 8 59535 1058 90567846
Breast cancer stage II 12.18 11.53 4 59539 35330 90533574
Prescribed underdose 12.18 11.53 19 59524 75000 90493904
Peripheral nerve injury 12.17 11.53 7 59536 732 90568172
Diplopia 12.13 11.53 44 59499 28670 90540234
Nephrolithiasis 12.12 11.53 64 59479 49021 90519883
Hormone level abnormal 12.08 11.53 12 59531 2861 90566043
Cholelithiasis 11.98 11.53 67 59476 52439 90516465
Neck pain 11.97 11.53 121 59422 113842 90455062
Pancreatic failure 11.94 11.53 9 59534 1483 90567421
Pulmonary embolism 11.93 11.53 135 59408 130685 90438219
Slow speech 11.91 11.53 10 59533 1923 90566981
Eye pain 11.89 11.53 59 59484 44109 90524795
Melaena 11.89 11.53 4 59539 34793 90534111
Plasma cell myeloma 11.84 11.53 6 59537 40822 90528082
Maternal exposure during pregnancy 11.80 11.53 166 59377 359897 90209007
Dermatitis contact 11.80 11.53 27 59516 13568 90555336
Arthralgia 11.58 11.53 407 59136 778115 89790789

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product physical issue 927.08 17.03 199 9178 3000 42608958
Product dose omission issue 223.11 17.03 218 9159 154147 42457811
Arteriospasm coronary 156.41 17.03 53 9324 4685 42607273
Migraine 128.18 17.03 76 9301 25338 42586620
Product quality issue 121.44 17.03 65 9312 17817 42594141
Headache 101.05 17.03 185 9192 239184 42372774
Medication overuse headache 82.40 17.03 17 9360 207 42611751
Brugada syndrome 69.42 17.03 20 9357 1033 42610925
Device deployment issue 69.06 17.03 18 9359 637 42611321
Device malfunction 65.09 17.03 38 9339 12289 42599669
Serotonin syndrome 64.49 17.03 50 9327 25795 42586163
Coronary artery dissection 60.35 17.03 14 9363 302 42611656
Throat tightness 54.44 17.03 31 9346 9568 42602390
Foetal exposure during pregnancy 52.16 17.03 58 9319 47253 42564705
Device issue 49.46 17.03 33 9344 13476 42598482
IIIrd nerve paresis 42.53 17.03 9 9368 125 42611833
Cluster headache 38.50 17.03 11 9366 551 42611407
Hyperhidrosis 36.79 17.03 69 9308 90443 42521515
Accidental exposure to product 33.44 17.03 31 9346 20362 42591596
Acute myocardial infarction 29.66 17.03 49 9328 58116 42553842
Application site pain 29.56 17.03 13 9364 2316 42609642
Cleft lip and palate 29.08 17.03 10 9367 922 42611036
Myofascial pain syndrome 28.85 17.03 8 9369 359 42611599
Injection site pain 28.54 17.03 48 9329 57750 42554208
Xanthelasma 27.98 17.03 6 9371 89 42611869
Application site burn 27.47 17.03 7 9370 226 42611732
Foetal growth restriction 27.13 17.03 16 9361 5267 42606691
Acute kidney injury 26.65 17.03 25 9352 367312 42244646
Chest pain 25.55 17.03 78 9299 139452 42472506
Gastrointestinal tract irritation 24.83 17.03 7 9370 334 42611624
Congenital genital malformation male 24.41 17.03 4 9373 11 42611947
Needle issue 24.22 17.03 18 9359 8709 42603249
Autonomic dysreflexia 23.14 17.03 5 9372 77 42611881
Craniosynostosis 23.13 17.03 7 9370 429 42611529
Drug ineffective 22.99 17.03 225 9152 629972 41981986
Anaemia 22.87 17.03 17 9360 280261 42331697
Product complaint 22.84 17.03 15 9362 5962 42605996
Chest discomfort 22.79 17.03 46 9331 63570 42548388
Paraesthesia 22.69 17.03 50 9327 73409 42538549
Disease progression 21.59 17.03 3 9374 143653 42468305
Foetal malnutrition 21.46 17.03 5 9372 110 42611848
Muscle tightness 21.37 17.03 14 9363 5539 42606419
Death 21.30 17.03 45 9332 471140 42140818
Sepsis 20.67 17.03 9 9368 199325 42412633
Electrocardiogram ST segment elevation 20.52 17.03 14 9363 5925 42606033
Anophthalmos 20.19 17.03 3 9374 3 42611955
Foetal hypokinesia 19.57 17.03 6 9371 384 42611574
Application site erythema 19.31 17.03 10 9367 2556 42609402
Aphasia 19.11 17.03 25 9352 24058 42587900
Postnatal growth restriction 18.71 17.03 5 9372 195 42611763
Stress cardiomyopathy 18.54 17.03 10 9367 2775 42609183
Irritable bowel syndrome 18.50 17.03 12 9365 4669 42607289
Pityriasis lichenoides et varioliformis acuta 17.87 17.03 3 9374 10 42611948
Anxiety 17.83 17.03 62 9315 118498 42493460
Thrombocytopenia 17.60 17.03 10 9367 190269 42421689
Depression 17.42 17.03 59 9318 111304 42500654
Renal artery dissection 17.25 17.03 3 9374 13 42611945
Seizure 17.23 17.03 62 9315 120499 42491459
Facial pain 17.03 17.03 11 9366 4249 42607709

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product physical issue 1291.51 12.19 329 52662 4707 110531601
Migraine 506.39 12.19 511 52480 171141 110365167
Application site erythema 408.36 12.19 138 52853 5472 110530836
Headache 350.30 12.19 1070 51921 881307 109655001
Product dose omission issue 332.40 12.19 571 52420 321211 110215097
Medication overuse headache 285.18 12.19 78 52913 1485 110534823
Application site burn 283.22 12.19 71 52920 946 110535362
Swollen tongue 265.86 12.19 225 52766 60137 110476171
Arteriospasm coronary 252.77 12.19 111 52880 8989 110527319
Application site pain 234.03 12.19 91 52900 5408 110530900
Swelling face 212.15 12.19 241 52750 92080 110444228
Reversible cerebral vasoconstriction syndrome 196.30 12.19 77 52914 4684 110531624
Application site discolouration 185.13 12.19 51 52940 998 110535310
Colitis ischaemic 182.75 12.19 111 52880 17639 110518669
Application site paraesthesia 178.51 12.19 32 52959 61 110536247
Device malfunction 177.75 12.19 125 52866 25433 110510875
Serotonin syndrome 170.29 12.19 174 52817 58979 110477329
Throat tightness 168.70 12.19 135 52856 33354 110502954
Dysphonia 165.65 12.19 193 52798 75736 110460572
Coronary artery dissection 158.74 12.19 47 52944 1201 110535107
Angioedema 146.46 12.19 207 52784 98293 110438015
Product quality issue 140.23 12.19 179 52812 77120 110459188
Drug ineffective for unapproved indication 138.18 12.19 206 52785 102632 110433676
Accidental exposure to product 134.76 12.19 142 52849 49866 110486442
IIIrd nerve paresis 116.06 12.19 26 52965 205 110536103
Anxiety 111.34 12.19 391 52600 344687 110191621
Drug ineffective 104.23 12.19 1148 51843 1519392 109016916
Application site pruritus 103.55 12.19 47 52944 4113 110532195
Acute kidney injury 101.60 12.19 93 52898 635337 109900971
Chest discomfort 100.70 12.19 243 52748 173605 110362703
Application site irritation 100.30 12.19 37 52954 1900 110534408
Endometriosis 98.60 12.19 46 52945 4288 110532020
Dizziness 96.58 12.19 618 52373 697575 109838733
Emotional distress 96.13 12.19 113 52878 44734 110491574
Application site warmth 94.03 12.19 23 52968 275 110536033
Application site urticaria 92.99 12.19 22 52969 226 110536082
Wrong technique in product usage process 91.22 12.19 156 52835 87192 110449116
Device deployment issue 90.17 12.19 43 52948 4210 110532098
Application site rash 88.42 12.19 36 52955 2414 110533894
Infusion related reaction 86.77 12.19 37 52954 381125 110155183
Post-traumatic neck syndrome 86.42 12.19 36 52955 2559 110533749
Death 84.18 12.19 128 52863 698741 109837567
Glossodynia 83.22 12.19 6 52985 221998 110314310
Muscle twitching 82.42 12.19 86 52905 29849 110506459
Wound 80.72 12.19 9 52982 234428 110301880
Soft tissue injury 80.62 12.19 33 52958 2243 110534065
Concussion 79.22 12.19 56 52935 11482 110524826
Hostility 78.49 12.19 34 52957 2662 110533646
Cluster headache 77.36 12.19 27 52964 1180 110535128
Pericarditis 76.49 12.19 8 52983 219106 110317202
Cerebral vasoconstriction 75.26 12.19 28 52963 1473 110534835
Libido increased 73.86 12.19 32 52959 2507 110533801
Lower respiratory tract infection 72.93 12.19 14 52977 243092 110293216
Migraine without aura 72.22 12.19 22 52969 621 110535687
Application site scar 71.91 12.19 17 52974 174 110536134
Sternal fracture 71.75 12.19 34 52957 3282 110533026
Anaemia 69.97 12.19 96 52895 546990 109989318
Stress cardiomyopathy 69.72 12.19 59 52932 15747 110520561
Systemic lupus erythematosus 69.55 12.19 18 52973 254320 110281988
Application site swelling 69.23 12.19 23 52968 864 110535444
Paraesthesia 69.11 12.19 289 52702 276232 110260076
Device issue 69.05 12.19 84 52907 34451 110501857
Vision blurred 69.03 12.19 175 52816 128847 110407461
Depression 66.73 12.19 315 52676 317020 110219288
Nausea 65.25 12.19 889 52102 1234801 109301507
Clonus 63.80 12.19 44 52947 8672 110527636
Suicidal ideation 62.83 12.19 139 52852 93798 110442510
Impaired healing 61.89 12.19 10 52981 196707 110339601
Febrile neutropenia 61.28 12.19 38 52953 316729 110219579
Cardiac failure 60.25 12.19 9 52982 187617 110348691
Injection site pain 59.37 12.19 204 52787 177718 110358590
Folliculitis 58.82 12.19 6 52985 167647 110368661
Hyperhidrosis 58.41 12.19 210 52781 187088 110349220
Cholecystitis chronic 58.13 12.19 43 52948 9457 110526851
Pituitary tumour benign 57.98 12.19 28 52963 2819 110533489
Application site vesicles 56.51 12.19 23 52968 1541 110534767
Arthropathy 56.30 12.19 34 52957 287488 110248820
General physical health deterioration 56.01 12.19 73 52918 425222 110111086
Disease progression 55.01 12.19 24 52967 244010 110292298
Neutropenia 55.00 12.19 59 52932 374561 110161747
Incorrect route of product administration 54.88 12.19 105 52886 63956 110472352
Pneumonia 54.35 12.19 226 52765 876488 109659820
Tremor 54.18 12.19 216 52775 202016 110334292
Feeling abnormal 54.14 12.19 200 52791 180511 110355797
Hepatic enzyme increased 53.58 12.19 45 52946 320847 110215461
Muscle tightness 52.93 12.19 49 52942 14713 110521595
Hot flush 52.64 12.19 105 52886 65931 110470377
Abortion spontaneous 52.34 12.19 73 52918 34209 110502099
Injection site haemorrhage 51.43 12.19 71 52920 32957 110503351
Pharyngeal swelling 51.20 12.19 44 52947 11988 110524320
Tension headache 51.06 12.19 40 52951 9578 110526730
Renal infarct 50.48 12.19 27 52964 3368 110532940
Vasospasm 49.34 12.19 21 52970 1575 110534733
Cervicogenic headache 49.07 12.19 13 52978 218 110536090
Pineal gland cyst 48.31 12.19 13 52978 232 110536076
Brugada syndrome 46.14 12.19 20 52971 1568 110534740
Sepsis 45.37 12.19 54 52937 327292 110209016
Injection site bruising 45.12 12.19 85 52906 51178 110485130
Hyponatraemia 45.09 12.19 24 52967 217629 110318679
Product substitution issue 44.34 12.19 55 52936 23006 110513302
Hypersensitivity 43.60 12.19 337 52654 403661 110132647
Middle insomnia 42.84 12.19 51 52940 20451 110515857
Thrombocytopenia 42.80 12.19 63 52928 348822 110187486
Type 2 diabetes mellitus 42.26 12.19 16 52975 177216 110359092
Drug intolerance 42.16 12.19 336 52655 406176 110130132
Application site dryness 42.06 12.19 12 52979 268 110536040
Application site exfoliation 41.39 12.19 14 52977 556 110535752
Contraindicated product administered 41.21 12.19 35 52956 248232 110288076
Joint range of motion decreased 41.12 12.19 5 52986 121827 110414481
Hyperreflexia 41 12.19 35 52956 9450 110526858
Pancytopenia 40.73 12.19 25 52966 209588 110326720
Drug specific antibody 40.68 12.19 22 52969 2806 110533502
Pyrexia 40.66 12.19 258 52733 898007 109638301
Chest pain 40.63 12.19 314 52677 376061 110160247
Liver injury 40.43 12.19 11 52980 150402 110385906
Hyperkalaemia 40.33 12.19 8 52983 135788 110400520
Nightmare 40.02 12.19 69 52922 38794 110497514
C-reactive protein abnormal 39.89 12.19 7 52984 129688 110406620
Foetal heart rate abnormal 39.07 12.19 14 52977 661 110535647
Angle closure glaucoma 38.91 12.19 23 52968 3476 110532832
Treatment failure 38.13 12.19 46 52945 277188 110259120
Stomatitis 38.07 12.19 44 52947 270198 110266110
Interstitial lung disease 37.81 12.19 10 52981 139324 110396984
Cerebral venous thrombosis 37.74 12.19 22 52969 3240 110533068
Platelet count decreased 37.62 12.19 33 52958 230410 110305898
Dysgeusia 37.49 12.19 95 52896 69890 110466418
Palpitations 37.11 12.19 163 52828 159049 110377259
Inflammation 36.23 12.19 24 52967 193214 110343094
Application site inflammation 36.14 12.19 12 52979 450 110535858
Synovitis 36.11 12.19 47 52944 274045 110262263
Device power source issue 35.90 12.19 16 52975 1341 110534967
Renal impairment 35.89 12.19 23 52968 188422 110347886
Flushing 35.72 12.19 121 52870 104615 110431693
Irritability 35.70 12.19 74 52917 47735 110488573
Meningoradiculitis 35.45 12.19 10 52981 214 110536094
Facet joint syndrome 35.20 12.19 3 52988 96825 110439483
Photophobia 35.12 12.19 52 52939 25719 110510589
Pulmonary fibrosis 34.90 12.19 4 52987 102038 110434270
Infection 34.07 12.19 77 52914 362123 110174185
Product administration interrupted 33.91 12.19 34 52957 11258 110525050
Vertigo 33.82 12.19 105 52886 86765 110449543
Joint swelling 33.43 12.19 105 52886 442740 110093568
Gastrointestinal disorder 33.42 12.19 40 52951 241912 110294396
Device difficult to use 33.22 12.19 43 52948 18762 110517546
Septic shock 33.17 12.19 17 52974 157511 110378797
Poor quality sleep 33.13 12.19 53 52938 28024 110508284
Renal failure 32.88 12.19 36 52955 226538 110309770
Body temperature increased 32.20 12.19 77 52914 54636 110481672
Hepatic function abnormal 31.83 12.19 3 52988 89292 110447016
Atrial fibrillation 31.68 12.19 38 52953 229604 110306704
Somnolence 31.44 12.19 247 52744 297202 110239106
Withdrawal syndrome 31.38 12.19 55 52936 31325 110504983
Pharyngeal oedema 31.29 12.19 39 52952 16389 110519919
Product complaint 31.26 12.19 36 52955 13936 110522372
Blister 30.97 12.19 38 52953 227338 110308970
Therapeutic response unexpected 30.91 12.19 47 52944 23796 110512512
Application site scab 30.73 12.19 9 52982 221 110536087
Extensor plantar response 30.35 12.19 16 52975 1939 110534369
Wound infection 30.12 12.19 5 52986 96460 110439848
Pre-existing condition improved 30.10 12.19 25 52966 6501 110529807
Peripheral venous disease 29.53 12.19 3 52988 84114 110452194
Myelosuppression 29.21 12.19 5 52986 94335 110441973
Decreased appetite 29.20 12.19 123 52868 475723 110060585
Lung disorder 29.12 12.19 26 52965 180021 110356287
Loss of consciousness 29.02 12.19 177 52814 196129 110340179
Acute myocardial infarction 28.75 12.19 97 52894 83680 110452628
Personality disorder 28.59 12.19 33 52958 12804 110523504
Somnambulism 28.43 12.19 24 52967 6381 110529927
Pneumonia aspiration 28.25 12.19 3 52988 81230 110455078
Gallbladder disorder 28.04 12.19 42 52949 20987 110515321
Rheumatoid arthritis 27.92 12.19 64 52927 299549 110236759
Post-traumatic stress disorder 27.82 12.19 24 52967 6572 110529736
Application site bruise 27.78 12.19 9 52982 312 110535996
Ill-defined disorder 27.41 12.19 21 52970 156832 110379476
Malignant neoplasm progression 27.30 12.19 26 52965 174541 110361767
Subclavian artery thrombosis 27.16 12.19 6 52985 44 110536264
Incorrect dose administered by device 27.14 12.19 24 52967 6790 110529518
Expired product administered 26.75 12.19 26 52965 8294 110528014
Hypotension 26.55 12.19 145 52846 523704 110012604
Migraine with aura 26.44 12.19 18 52973 3474 110532834
Product adhesion issue 26.40 12.19 17 52974 2989 110533319
Temperature intolerance 26.38 12.19 33 52958 13917 110522391
Transient global amnesia 26.19 12.19 12 52979 1073 110535235
Pleural effusion 26.04 12.19 28 52963 177681 110358627
Myalgia 25.93 12.19 189 52802 222192 110314116
Hyperprolactinaemia 25.88 12.19 23 52968 6552 110529756
Haemoglobin decreased 25.80 12.19 50 52941 248677 110287631
Application site reaction 25.70 12.19 11 52980 836 110535472
Gastrointestinal haemorrhage 25.48 12.19 25 52966 165493 110370815
Grip strength decreased 25.38 12.19 4 52987 80170 110456138
Tinnitus 25.27 12.19 75 52916 60465 110475843
Application site discomfort 25.26 12.19 9 52982 418 110535890
Swelling 25.26 12.19 85 52906 350956 110185352
Rash maculo-papular 25.16 12.19 3 52988 74219 110462089
Meconium in amniotic fluid 24.76 12.19 7 52984 151 110536157
Electrocardiogram ST segment elevation 24.65 12.19 26 52965 9134 110527174
Blood creatinine increased 24.45 12.19 31 52960 182858 110353450
Rib fracture 23.74 12.19 51 52940 33719 110502589
Seizure 23.54 12.19 184 52807 221001 110315307
Mobility decreased 23.53 12.19 49 52942 237373 110298935
Osteoarthritis 23.35 12.19 32 52959 182591 110353717
Multiple organ dysfunction syndrome 23.25 12.19 23 52968 151687 110384621
Bursitis 23.21 12.19 17 52974 129901 110406407
Injection site erythema 23.15 12.19 98 52893 94078 110442230
Major depression 23.15 12.19 27 52964 10594 110525714
Vasoconstriction 22.86 12.19 11 52980 1099 110535209
Drug dependence 22.84 12.19 64 52927 49956 110486352
Burning sensation 22.75 12.19 79 52912 69133 110467175
Head discomfort 22.60 12.19 36 52955 18964 110517344
Secondary adrenocortical insufficiency 22.59 12.19 18 52973 4416 110531892
Disturbance in attention 22.36 12.19 73 52918 61922 110474386
Illness 22.17 12.19 88 52903 82083 110454225
Hypoaesthesia 22.07 12.19 239 52752 313984 110222324
Hypercholesterolaemia 21.99 12.19 8 52983 90829 110445479
Multiple sclerosis relapse 21.70 12.19 63 52928 50177 110486131
Abdominal discomfort 21.64 12.19 106 52885 393752 110142556
Peripheral swelling 21.48 12.19 110 52881 403924 110132384
Pain 21.47 12.19 604 52387 954351 109581957
Delirium 21.24 12.19 20 52971 135005 110401303
Foreign body in reproductive tract 21.11 12.19 10 52981 964 110535344
Oedema 21.09 12.19 43 52948 209933 110326375
Phonophobia 21.03 12.19 9 52982 684 110535624
Blood alkaline phosphatase 21.02 12.19 7 52984 265 110536043
Panic attack 20.68 12.19 44 52947 28896 110507412
Blood pressure systolic increased 20.62 12.19 7 52984 82984 110453324
Dependence 20.50 12.19 14 52977 2715 110533593
Muscle contractions involuntary 20.45 12.19 17 52974 4427 110531881
Burns third degree 20.42 12.19 8 52983 485 110535823
Liver disorder 20.19 12.19 23 52968 142220 110394088
Basilar migraine 20.13 12.19 5 52986 64 110536244
Sunburn 20.10 12.19 17 52974 4531 110531777
Respiratory failure 20.05 12.19 46 52945 215286 110321022
Xanthelasma 19.91 12.19 6 52985 163 110536145
Drug-induced liver injury 19.82 12.19 17 52974 120050 110416258
Blood bilirubin increased 19.60 12.19 6 52985 75966 110460342
Impaired quality of life 19.59 12.19 44 52947 29973 110506335
Biliary dyskinesia 19.58 12.19 13 52978 2408 110533900
Renal tubular acidosis 19.57 12.19 17 52974 4698 110531610
Hyperacusis 19.51 12.19 14 52977 2938 110533370
Human chorionic gonadotropin decreased 19.39 12.19 5 52986 75 110536233
Optic ischaemic neuropathy 19.36 12.19 16 52975 4131 110532177
Blood cholesterol increased 19.28 12.19 37 52954 184748 110351560
Application site papules 19.21 12.19 5 52986 78 110536230
Complement factor C4 decreased 19.04 12.19 7 52984 356 110535952
Product leakage 18.95 12.19 11 52980 1607 110534701
Wheezing 18.90 12.19 61 52930 255169 110281139
Myofascial pain syndrome 18.86 12.19 13 52978 2560 110533748
Red blood cell sedimentation rate increased 18.78 12.19 7 52984 78295 110458013
Complement factor C3 decreased 18.71 12.19 7 52984 374 110535934
Device leakage 18.53 12.19 30 52961 16018 110520290
Gamma-glutamyltransferase abnormal 18.52 12.19 9 52982 918 110535390
Ovarian neoplasm 18.45 12.19 8 52983 628 110535680
Multiple sclerosis 18.28 12.19 39 52952 25659 110510649
Torsade de pointes 18.08 12.19 36 52955 22564 110513744
Eye pain 18.07 12.19 59 52932 50040 110486268
Irritable bowel syndrome 17.92 12.19 32 52959 164183 110372125
Hypertonia 17.71 12.19 21 52970 8385 110527923
Drug specific antibody present 17.65 12.19 21 52970 8413 110527895
Teratogenicity 17.63 12.19 6 52985 243 110536065
Infection reactivation 17.52 12.19 15 52976 4066 110532242
Hormone level abnormal 17.38 12.19 12 52979 2368 110533940
Injection site swelling 17.34 12.19 67 52924 61723 110474585
Surgery 17.09 12.19 51 52940 41232 110495076
Asthma 16.94 12.19 189 52802 250102 110286206
Transverse sinus thrombosis 16.90 12.19 8 52983 770 110535538
Eyelid ptosis 16.89 12.19 26 52965 13301 110523007
Post viral fatigue syndrome 16.81 12.19 6 52985 280 110536028
Lip swelling 16.80 12.19 58 52933 50609 110485699
Superior sagittal sinus thrombosis 16.67 12.19 9 52982 1144 110535164
Nipple pain 16.65 12.19 9 52982 1147 110535161
Sciatica 16.62 12.19 12 52979 92387 110443921
Oedema peripheral 16.62 12.19 91 52900 328569 110207739
Immunisation reaction 16.61 12.19 8 52983 801 110535507
Aphasia 16.58 12.19 64 52927 58933 110477375
Injection site laceration 16.49 12.19 5 52986 139 110536169
Product use issue 16.48 12.19 85 52906 311610 110224698
Hypoglycaemia 16.23 12.19 19 52972 116085 110420223
Nail disorder 16.02 12.19 4 52987 57931 110478377
Bone marrow failure 15.98 12.19 4 52987 57844 110478464
Gallbladder injury 15.74 12.19 9 52982 1279 110535029
Application site erosion 15.67 12.19 6 52985 342 110535966
Large intestinal ulcer haemorrhage 15.65 12.19 6 52985 343 110535965
Incorrect disposal of product 15.48 12.19 9 52982 1319 110534989
Mucosal inflammation 15.40 12.19 14 52977 96127 110440181
Peripheral coldness 15.40 12.19 30 52961 18510 110517798
Acute oesophageal mucosal lesion 15.17 12.19 5 52986 183 110536125
Renal artery dissection 14.92 12.19 3 52988 13 110536295
Anger 14.87 12.19 30 52961 18977 110517331
Drug withdrawal syndrome 14.81 12.19 46 52945 38008 110498300
Balance disorder 14.71 12.19 101 52890 116459 110419849
International normalised ratio increased 14.68 12.19 12 52979 86760 110449548
Neutrophil count decreased 14.66 12.19 22 52969 120919 110415389
Cytomegalovirus infection 14.59 12.19 4 52987 54440 110481868
Frequent bowel movements 14.59 12.19 8 52983 71382 110464926
Optic neuritis 14.49 12.19 22 52969 11125 110525183
Incorrect dose administered 14.40 12.19 92 52899 103549 110432759
Anaphylactic reaction 14.40 12.19 99 52892 114201 110422107
Drug hypersensitivity 14.33 12.19 301 52690 453789 110082519
Cardiac failure congestive 14.26 12.19 32 52959 150968 110385340
Injection site injury 14.26 12.19 8 52983 1096 110535212
Amyloidoma 13.96 12.19 3 52988 19 110536289
Diarrhoea 13.92 12.19 428 52563 1139077 109397231
Epistaxis 13.69 12.19 26 52965 130346 110405962
Left atrial volume increased 13.63 12.19 4 52987 99 110536209
Cognitive disorder 13.62 12.19 80 52911 87431 110448877
Neoplasm progression 13.55 12.19 7 52984 64588 110471720
Oxygen saturation decreased 13.46 12.19 35 52956 156947 110379361
Hypoxia 13.45 12.19 26 52965 129489 110406819
Neck pain 13.41 12.19 103 52888 123027 110413281
Hip arthroplasty 13.36 12.19 5 52986 55808 110480500
Gastrointestinal tract irritation 13.36 12.19 7 52984 838 110535470
Mouth swelling 13.28 12.19 17 52974 7337 110528971
Lower limb fracture 13.27 12.19 10 52981 75338 110460970
Respiratory disorder 13.19 12.19 9 52982 71373 110464935
Cerebral venous sinus thrombosis 13.17 12.19 11 52980 2884 110533424
Trismus 13.11 12.19 16 52975 6580 110529728
Hepatotoxicity 13.11 12.19 7 52984 63393 110472915
Product dispensing error 13.03 12.19 26 52965 16319 110519989
Ischaemic cerebral infarction 13 12.19 11 52980 2934 110533374
Dysmenorrhoea 12.97 12.19 12 52979 3598 110532710
Depressive symptom 12.97 12.19 18 52973 8396 110527912
Pancreatic failure 12.95 12.19 10 52981 2344 110533964
Plasma cell myeloma 12.94 12.19 7 52984 62929 110473379
Liver function test increased 12.91 12.19 14 52977 88534 110447774
Cytokine release syndrome 12.82 12.19 9 52982 70297 110466011
Gait inability 12.80 12.19 29 52962 136347 110399961
Bronchitis 12.71 12.19 123 52868 156909 110379399
Insomnia 12.70 12.19 243 52748 360347 110175961
Choking sensation 12.67 12.19 13 52978 4423 110531885
Prescribed overdose 12.60 12.19 14 52977 87567 110448741
Psoriatic arthropathy 12.59 12.19 50 52941 196711 110339597
Alopecia 12.53 12.19 113 52878 364640 110171668
Autoimmune disorder 12.45 12.19 8 52983 65475 110470833
Helicobacter infection 12.42 12.19 45 52946 181832 110354476
Drug-disease interaction 12.38 12.19 9 52982 1927 110534381
Complication of device insertion 12.28 12.19 18 52973 8820 110527488
Melaena 12.27 12.19 9 52982 68748 110467560
Temporomandibular joint syndrome 12.27 12.19 12 52979 3857 110532451
Haematuria 12.24 12.19 13 52978 82992 110453316
Cholecystectomy 12.20 12.19 20 52971 10789 110525519

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N02CC01 NERVOUS SYSTEM
ANALGESICS
ANTIMIGRAINE PREPARATIONS
Selective serotonin (5HT1) agonists
ATC N02CC51 NERVOUS SYSTEM
ANALGESICS
ANTIMIGRAINE PREPARATIONS
Selective serotonin (5HT1) agonists
FDA MoA N0000175763 Serotonin 1b Receptor Agonists
FDA MoA N0000175764 Serotonin 1d Receptor Agonists
FDA EPC N0000175765 Serotonin-1b and Serotonin-1d Receptor Agonist
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35941 serotonergic agonist
CHEBI has role CHEBI:50514 vasoconstrictor agent
CHEBI has role CHEBI:74518 anti-obesity agent
MeSH PA D002317 Cardiovascular Agents
MeSH PA D014662 Vasoconstrictor Agents
MeSH PA D017366 Serotonin Receptor Agonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018490 Serotonin Agents
MeSH PA D058825 Serotonin 5-HT1 Receptor Agonists

Related Drugs by ATC class:

N02CC Selective serotonin (5HT1) agonists 8 drugs
almotriptaneletriptanfrovatriptanlasmiditannaproxennaratriptanrizatriptanzolmitriptan

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Migraine indication 37796009 DOID:6364
Cluster headache syndrome indication 193031009
Tachyarrhythmia contraindication 6285003
Alcoholism contraindication 7200002
Hypercholesterolemia contraindication 13644009
Myocardial infarction contraindication 22298006 DOID:5844
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal ulcer contraindication 40845000
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Hemiplegic migraine contraindication 59292006
Hepatic failure contraindication 59927004
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Vascular insufficiency of intestine contraindication 82196007
Epilepsy contraindication 84757009 DOID:1826
Prinzmetal angina contraindication 87343002
Kidney disease contraindication 90708001 DOID:557
Liver function tests abnormal contraindication 166603001
Angina pectoris contraindication 194828000
Cerebrovascular accident contraindication 230690007
Coronary artery bypass graft contraindication 232717009
Disease of liver contraindication 235856003 DOID:409
Transient ischemic attack contraindication 266257000 DOID:224
Esophageal dysmotility contraindication 266434009 DOID:9192
Edema contraindication 267038008
Anemia contraindication 271737000 DOID:2355
Cerebral ischemia contraindication 287731003
Pregnancy, function contraindication 289908002
Thromboembolic disorder contraindication 371039008
Serotonin syndrome contraindication 371089000
Cardiovascular event risk contraindication 395112001
Peripheral vascular disease contraindication 400047006
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Hypertensive urgency contraindication 443482000
Smokes tobacco daily contraindication 449868002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.23 acidic
pKa2 13.42 acidic
pKa3 8.28 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
500MG;EQ 85MG BASE TREXIMET CURRAX N021926 April 15, 2008 RX TABLET ORAL 7332183 Oct. 2, 2025 TREATMENT OF MIGRAINE
60MG;EQ 10MG BASE TREXIMET CURRAX N021926 May 14, 2015 DISCN TABLET ORAL 7332183 Oct. 2, 2025 ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 11571531 Feb. 23, 2026 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
10MG/SPRAY TOSYMRA TONIX MEDS N210884 Jan. 25, 2019 RX SPRAY NASAL 8440631 May 9, 2026 ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10124132 March 6, 2027 ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10124132 March 6, 2027 ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10124132 March 6, 2027 TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 7973058 April 12, 2027 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 8155737 April 12, 2027 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 8470853 April 12, 2027 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 9427578 April 12, 2027 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ALSUMA MERIDIAN MEDCL N022377 June 29, 2010 DISCN INJECTABLE SUBCUTANEOUS 7811254 Aug. 26, 2027 ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 8875704 April 7, 2028 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 8366600 April 21, 2029 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10076615 July 30, 2029 ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10076615 July 30, 2029 METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10076615 July 30, 2029 TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
10MG/SPRAY TOSYMRA TONIX MEDS N210884 Jan. 25, 2019 RX SPRAY NASAL 10603305 June 16, 2030 ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY TOSYMRA TONIX MEDS N210884 Jan. 25, 2019 RX SPRAY NASAL 11337962 June 16, 2030 ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY TOSYMRA TONIX MEDS N210884 Jan. 25, 2019 RX SPRAY NASAL 9610280 June 16, 2030 ACUTE TREATMENT OF MIGRAINE
10MG/SPRAY TOSYMRA TONIX MEDS N210884 Jan. 25, 2019 RX SPRAY NASAL 9974770 June 16, 2030 ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 9649456 Oct. 21, 2030 ACUTE TREATMENT OF MIGRAINE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 9649456 Oct. 21, 2030 ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 9649456 Oct. 21, 2030 TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 8983594 Nov. 19, 2030 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
10MG/SPRAY TOSYMRA TONIX MEDS N210884 Jan. 25, 2019 RX SPRAY NASAL 9211282 July 19, 2031 ACUTE TREATMENT OF MIGRAINE
EQ 6.5MG BASE/4HR ZECUITY TEVA BRANDED PHARM N202278 Jan. 17, 2013 DISCN SYSTEM IONTOPHORESIS 9327114 Oct. 8, 2032 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
EQ 11MG BASE ONZETRA XSAIL CURRAX N206099 Jan. 27, 2016 RX POWDER NASAL 10478574 Nov. 4, 2033 METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) ZEMBRACE SYMTOUCH TONIX MEDS N208223 Jan. 28, 2016 RX SOLUTION SUBCUTANEOUS 10537554 Jan. 29, 2036 TREATMENT OF MIGRAINE
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) ZEMBRACE SYMTOUCH TONIX MEDS N208223 Jan. 28, 2016 RX SOLUTION SUBCUTANEOUS 11364224 Jan. 29, 2036 TREATMENT OF MIGRAINE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 8.92 CHEMBL CHEMBL
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 8.26 CHEMBL CHEMBL
5-hydroxytryptamine receptor 2C GPCR IC50 8.14 CHEMBL
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 5.60 IUPHAR
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 6 IUPHAR
5-hydroxytryptamine receptor 3A Ion channel IC50 8.03 CHEMBL
5-hydroxytryptamine receptor 5A GPCR IC50 6.30 CHEMBL
5-hydroxytryptamine receptor 1F GPCR Ki 7.59 CHEMBL
5-hydroxytryptamine receptor 1E GPCR IC50 5.26 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 5.17 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 6.64 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 6.42 CHEMBL
5-hydroxytryptamine receptor 1B GPCR Ki 7.64 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 6.19 CHEMBL
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 6.60 IUPHAR
5-hydroxytryptamine receptor 1D GPCR IC50 7.70 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 6.35 CHEMBL
5-hydroxytryptamine receptor 1D GPCR IC50 7.21 CHEMBL
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 5.20 IUPHAR
5-hydroxytryptamine receptor 1B GPCR Ki 8.19 CHEMBL
5-hydroxytryptamine 1D receptor GPCR IC50 7.23 CHEMBL
5-hydroxytryptamine receptor 5A GPCR AGONIST Ki 4.80 IUPHAR

External reference:

IDSource
4021050 VUID
N0000148514 NUI
D00451 KEGG_DRUG
103628-48-4 SECONDARY_CAS_RN
4020790 VANDF
4021050 VANDF
C0075632 UMLSCUI
CHEBI:10650 CHEBI
CHEMBL128 ChEMBL_ID
CHEMBL1201150 ChEMBL_ID
DB00669 DRUGBANK_ID
D018170 MESH_DESCRIPTOR_UI
5358 PUBCHEM_CID
54 IUPHAR_LIGAND_ID
6125 INN_ID
8R78F6L9VO UNII
37418 RXNORM
158892 MMSL
166806 MMSL
25268 MMSL
31925 MMSL
5536 MMSL
d03160 MMSL
004044 NDDF
004045 NDDF
322822007 SNOMEDCT_US
395892000 SNOMEDCT_US
96215002 SNOMEDCT_US
8R78F6L9VO INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SUMATRIPTAN HUMAN PRESCRIPTION DRUG LABEL 1 0143-9638 INJECTION 6 mg SUBCUTANEOUS ANDA 28 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0478 INJECTION 6 mg SUBCUTANEOUS NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0479 INJECTION 6 mg SUBCUTANEOUS NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0735 TABLET, FILM COATED 25 mg ORAL NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0736 TABLET, FILM COATED 50 mg ORAL NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0737 TABLET, FILM COATED 100 mg ORAL NDA 27 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 0173-0739 INJECTION 4 mg SUBCUTANEOUS NDA 27 sections
ZEMBRACE SYMTOUCH HUMAN PRESCRIPTION DRUG LABEL 1 0245-0809 INJECTION, SOLUTION 3 mg SUBCUTANEOUS NDA 31 sections
TOSYMRA HUMAN PRESCRIPTION DRUG LABEL 1 0245-0812 SPRAY 10 mg NASAL NDA 31 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5630 TABLET, FILM COATED 25 mg ORAL ANDA 28 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5631 TABLET, FILM COATED 50 mg ORAL ANDA 28 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5632 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Sumatriptan HUMAN PRESCRIPTION DRUG LABEL 1 0527-1818 SPRAY 5 mg NASAL ANDA 28 sections
Sumatriptan HUMAN PRESCRIPTION DRUG LABEL 1 0527-1859 SPRAY 20 mg NASAL ANDA 28 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 16590-300 TABLET, FILM COATED 100 mg ORAL NDA 13 sections
SUMATRIPTAN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 16590-408 TABLET 50 mg ORAL ANDA 27 sections
SUMATRIPTAN SUCCINATE HUMAN PRESCRIPTION DRUG LABEL 1 16590-950 TABLET 25 mg ORAL ANDA 27 sections
Sumatriptan Human Prescription Drug Label 1 16714-796 TABLET 25 mg ORAL ANDA 27 sections
Sumatriptan Human Prescription Drug Label 1 16714-797 TABLET 50 mg ORAL ANDA 27 sections
Sumatriptan Human Prescription Drug Label 1 16714-798 TABLET 100 mg ORAL ANDA 27 sections
Sumatriptan and Naproxen Sodium Human Prescription Drug Label 2 16714-891 TABLET, FILM COATED 85 mg ORAL ANDA 32 sections
IMITREX HUMAN PRESCRIPTION DRUG LABEL 1 21695-154 TABLET, FILM COATED 50 mg ORAL NDA 26 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 21695-872 TABLET 25 mg ORAL ANDA 27 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 21695-873 TABLET 50 mg ORAL ANDA 27 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 21695-874 TABLET 100 mg ORAL ANDA 27 sections
TREXIMET HUMAN PRESCRIPTION DRUG LABEL 2 21695-954 TABLET, FILM COATED 85 mg ORAL NDA 29 sections
sumatriptan succinate HUMAN PRESCRIPTION DRUG LABEL 1 33261-662 TABLET, FILM COATED 25 mg ORAL ANDA 26 sections
Sumatriptan HUMAN PRESCRIPTION DRUG LABEL 1 33261-663 TABLET 50 mg ORAL ANDA 27 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 35356-438 TABLET 100 mg ORAL ANDA 25 sections
Sumatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 35356-439 TABLET 50 mg ORAL ANDA 25 sections